1. Home
  2. ACIU vs ESEA Comparison

ACIU vs ESEA Comparison

Compare ACIU & ESEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACIU
  • ESEA
  • Stock Information
  • Founded
  • ACIU 2003
  • ESEA 2005
  • Country
  • ACIU Switzerland
  • ESEA Greece
  • Employees
  • ACIU N/A
  • ESEA N/A
  • Industry
  • ACIU Biotechnology: Pharmaceutical Preparations
  • ESEA Marine Transportation
  • Sector
  • ACIU Health Care
  • ESEA Consumer Discretionary
  • Exchange
  • ACIU Nasdaq
  • ESEA Nasdaq
  • Market Cap
  • ACIU 189.1M
  • ESEA 208.2M
  • IPO Year
  • ACIU 2016
  • ESEA 2006
  • Fundamental
  • Price
  • ACIU $2.03
  • ESEA $48.25
  • Analyst Decision
  • ACIU Strong Buy
  • ESEA Strong Buy
  • Analyst Count
  • ACIU 1
  • ESEA 1
  • Target Price
  • ACIU $12.00
  • ESEA $62.00
  • AVG Volume (30 Days)
  • ACIU 120.2K
  • ESEA 53.7K
  • Earning Date
  • ACIU 08-05-2025
  • ESEA 08-05-2025
  • Dividend Yield
  • ACIU N/A
  • ESEA 5.36%
  • EPS Growth
  • ACIU N/A
  • ESEA 21.86
  • EPS
  • ACIU N/A
  • ESEA 18.62
  • Revenue
  • ACIU $32,014,254.00
  • ESEA $222,525,034.00
  • Revenue This Year
  • ACIU N/A
  • ESEA $7.22
  • Revenue Next Year
  • ACIU $533.21
  • ESEA $1.75
  • P/E Ratio
  • ACIU N/A
  • ESEA $2.61
  • Revenue Growth
  • ACIU 91.20
  • ESEA 14.62
  • 52 Week Low
  • ACIU $1.43
  • ESEA $24.58
  • 52 Week High
  • ACIU $4.26
  • ESEA $50.82
  • Technical
  • Relative Strength Index (RSI)
  • ACIU 56.32
  • ESEA 65.64
  • Support Level
  • ACIU $2.03
  • ESEA $46.59
  • Resistance Level
  • ACIU $2.15
  • ESEA $49.52
  • Average True Range (ATR)
  • ACIU 0.14
  • ESEA 1.76
  • MACD
  • ACIU -0.00
  • ESEA -0.07
  • Stochastic Oscillator
  • ACIU 79.28
  • ESEA 83.21

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

Share on Social Networks: